
Currently out of the existing stock ratings of Colin Bristow, 108 are a BUY (61.71%), 67 are a HOLD (38.29%).
Analyst Colin Bristow, currently employed at UBS, has had 68.31% of price targets met with an average potential upside of 36.92%, reached in 379 days on average. Previously, Colin Bristow worked at BAML.
Colin Bristow has documented 349 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBTX, at 30-Apr-2026.
Analyst best performing recommendations are on CADL.
The best stock recommendation documented was for BIIB (BIOGEN) on 6/2/2021. The price target of $311 was fulfilled within 5 days with a profit of $41.65 (15.46%), with a performance score of 30.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
5 years 6 months 16 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 03-May-2021
$173
$156
5 years 6 months 18 days ago
(03-May-2021)
17/29 (58.62%)
$2.73 (1.60%)
650
Hold Since 04-Feb-2021
$190
$190
5 years 6 months 26 days ago
(26-Apr-2021)
11/14 (78.57%)
$23 (13.77%)
420
Buy Since 06-Sep-2019
$175
$165
5 years 9 months 17 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Buy Since 17-Jul-2017
$166
$175
5 years 9 months 17 days ago
(04-Feb-2021)
32/33 (96.97%)
$10.41 (6.69%)
867
What Year was the first public recommendation made by Colin Bristow?